Selma Ugurel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Selma Ugurel has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Dirk Schadendorf
Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
6 shared publications- Dirk Schadendorf
Department of Dermatology, University of Essen, Essen
5 shared publications - Andreas Hochhaus
Klinik für Innere Medizin II, Universitätsklinikum Jena, Comprehensive Cancer Center Central Germany, Campus Jena, Jena, Germany
3 shared publications Werner Rittgen
Central Unit of Biostatistics, German Cancer Research Center, Heidelberg, Germany
3 shared publicationsA. Zimpfer
2 shared publicationsAntje Sucker
Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
2 shared publications
Latest Publications
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8526
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.
8526 Background: There is no standard of care for advanced metastatic melanoma (MM). Therefore the combination of a multi-kinase inhibitor such as sorafenib, and pegylated interferon alfa-2b (PegIFN), as previously used in renal cell cancer with some success, could potentially lead to an improved anti-tumoral response. Methods: Patients (pts) with previously untreated (excluding immunotherapy in the adjuvant setting), stage IV MM without brain metastasis, ECOG performance status 0-1 were eligible. All pts received PegIFN 3 μ g/kg weekly once per week, and sorafenib 400 mg BID until progressive disease (PD). The primary endpoint was disease control rate (DCR) defined as CR+PR+SD after 8 weeks of treatment. Results: From February 2008 to February 2009, 55 pts were enrolled (ITT population). The median age was 64 years (range: 20-85); Pts were categorized as following: stage IV M1a/b/c = 3/9/43. 41 pts (75%) received at least 8 weeks of treatment. Prior to 8 weeks evaluation, 9 pts withdrew due to toxicity, 2 revoked consent, and 3 had overt PD. At 8 weeks, 3 pts (5.5%) had a PR, 14 (25.5%) had a SD, resulting in a 31% DCR. Median PFS in these pts was 2.1 months (95%CI: 1.9–2.3). The toxicity of this combination was mainly haematological. Serious brain and GI bleeding complications occurred in 4 pts, where 2 had a fatal outcome. Other grade ¾ toxicities were fatigue and flu- like symptoms. Conclusions: The combination of sorafenib and PegIFN showed modest clinical activity and some serious side effects including fatal bleeding complications. Due to these findings further testing of this combination is not warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 8526
Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial.
8526 Background: There is no standard of care for advanced metastatic melanoma (MM). Therefore the combination of a multi-kinase inhibitor such as sorafenib, and pegylated interferon alfa-2b (PegIFN), as previously used in renal cell cancer with some success, could potentially lead to an improved anti-tumoral response. Methods: Patients (pts) with previously untreated (excluding immunotherapy in the adjuvant setting), stage IV MM without brain metastasis, ECOG performance status 0-1 were eligible. All pts received PegIFN 3 μ g/kg weekly once per week, and sorafenib 400 mg BID until progressive disease (PD). The primary endpoint was disease control rate (DCR) defined as CR+PR+SD after 8 weeks of treatment. Results: From February 2008 to February 2009, 55 pts were enrolled (ITT population). The median age was 64 years (range: 20-85); Pts were categorized as following: stage IV M1a/b/c = 3/9/43. 41 pts (75%) received at least 8 weeks of treatment. Prior to 8 weeks evaluation, 9 pts withdrew due to toxicity, 2 revoked consent, and 3 had overt PD. At 8 weeks, 3 pts (5.5%) had a PR, 14 (25.5%) had a SD, resulting in a 31% DCR. Median PFS in these pts was 2.1 months (95%CI: 1.9–2.3). The toxicity of this combination was mainly haematological. Serious brain and GI bleeding complications occurred in 4 pts, where 2 had a fatal outcome. Other grade ¾ toxicities were fatigue and flu- like symptoms. Conclusions: The combination of sorafenib and PegIFN showed modest clinical activity and some serious side effects including fatal bleeding complications. Due to these findings further testing of this combination is not warranted. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough Bayer Health Care, Schering-Plough
- 1 March 2007
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 5 (3) , 261
Arbeitsgemeinschaft Dermatologische Onkologie ADO
- 1 March 2007
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 5 (3) , 261
Arbeitsgemeinschaft Dermatologische Onkologie ADO
- Open Access
- 21 February 2007
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (2) , e236
B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
In melanoma, the RAS/RAF/MEK/ERK signalling pathway is an area of great interest, because it regulates tumor cell proliferation and survival. A varying mutation rate has been reported for B-RAF and N-RAS, which has been largely attributed to the differential source of tumor DNA analyzed, e.g., fixed tumor tissues or in vitro propagated melanoma cells. Notably, this variation also interfered with interpreting the impact of these mutations on the clinical course of the disease. Consequently, we investigated the mutational profile of B-RAF and N-RAS in biopsies and corresponding cell lines from metastatic tumor lesions of 109 melanoma patients (AJCC stage III/IV), and its respective impact on survival. 97 tissue biopsies and 105 biopsy-derived cell lines were screened for B-RAF and N-RAS mutations by PCR single strand conformation polymorphism and DNA sequencing. Mutations were correlated with patient survival data obtained within a median follow-up time of 31 months. B-RAF mutations were detected in 55% tissues and 51% cell lines, N-RAS mutations in 23% tissues and 25% cell lines, respectively. There was strong concordance between the mutational status of tissues and corresponding cell lines, showing a differing status for B-RAF in only 5% and N-RAS in only 6%, respectively. Patients with tumors carrying mutated B-RAF showed an impaired median survival (8.0 versus 11.8 months, p = 0.055, tissues; 7.1 versus 9.3 months, p = 0.068, cell lines), whereas patients with N-RAS-mutated tumors presented with a favorable prognosis (median survival 12.5 versus 7.9 months, p = 0.084, tissues; 15.4 versus 6.8 months, p = 0.0008, cell lines), each in comparison with wildtype gene status. Multivariate analysis qualified N-RAS (p = 0.006) but not B-RAF mutation status as an independent prognostic factor of overall survival. Our findings demonstrate that B-RAF and N-RAS mutations are well preserved during short term in vitro propagation and, most importantly, differentially impact the outcome of melanoma patients.
- 21 February 2007
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (2) , e236
Open AccessB-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
In melanoma, the RAS/RAF/MEK/ERK signalling pathway is an area of great interest, because it regulates tumor cell proliferation and survival. A varying mutation rate has been reported for B-RAF and N-RAS, which has been largely attributed to the differential source of tumor DNA analyzed, e.g., fixed tumor tissues or in vitro propagated melanoma cells. Notably, this variation also interfered with interpreting the impact of these mutations on the clinical course of the disease. Consequently, we investigated the mutational profile of B-RAF and N-RAS in biopsies and corresponding cell lines from metastatic tumor lesions of 109 melanoma patients (AJCC stage III/IV), and its respective impact on survival. 97 tissue biopsies and 105 biopsy-derived cell lines were screened for B-RAF and N-RAS mutations by PCR single strand conformation polymorphism and DNA sequencing. Mutations were correlated with patient survival data obtained within a median follow-up time of 31 months. B-RAF mutations were detected in 55% tissues and 51% cell lines, N-RAS mutations in 23% tissues and 25% cell lines, respectively. There was strong concordance between the mutational status of tissues and corresponding cell lines, showing a differing status for B-RAF in only 5% and N-RAS in only 6%, respectively. Patients with tumors carrying mutated B-RAF showed an impaired median survival (8.0 versus 11.8 months, p = 0.055, tissues; 7.1 versus 9.3 months, p = 0.068, cell lines), whereas patients with N-RAS-mutated tumors presented with a favorable prognosis (median survival 12.5 versus 7.9 months, p = 0.084, tissues; 15.4 versus 6.8 months, p = 0.0008, cell lines), each in comparison with wildtype gene status. Multivariate analysis qualified N-RAS (p = 0.006) but not B-RAF mutation status as an independent prognostic factor of overall survival. Our findings demonstrate that B-RAF and N-RAS mutations are well preserved during short term in vitro propagation and, most importantly, differentially impact the outcome of melanoma patients.
- Open Access
- 13 January 2007
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 298 (10) , 469-477
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
- 13 January 2007
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 298 (10) , 469-477
Open AccessSerologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
Biomarkers are important tools in clinical diagnosis and prognostic classification of various cutaneous malignancies. Besides clinical and histopathological aspects (e.g. anatomic site and type of the primary tumour, tumour size and invasion depth, ulceration, vascular invasion), an increasing variety of molecular markers have been identified, providing the possibility of a more detailed diagnostic and prognostic subgrouping of tumour entities, up to even changing existing classification systems. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. We, here, give an overview on currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies, malignant melanoma, squamous cell carcinoma and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
- 15 September 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (18) , 5454-5463
In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group
Purpose:In vitro sensitivity assays are promising tools to predict the individual outcome of different chemotherapy regimens. However, a direct association between in vitro and in vivo chemosensitivity has to be shown by clinical studies. This multicenter phase II trial was aimed to investigate the efficacy of a sensitivity-directed, first-line chemotherapy in metastasized melanoma patients, and to prove an association between in vitro sensitivity and therapy outcome. Patients and Methods: The primary study end point was objective response; secondary end points were safety, overall survival, and progression-free survival. Viable tumor cells obtained from metastatic lesions were tested for chemosensitivity to seven single drugs and five drug combinations using an ATP-based luminescence viability assay. Results: Out of 82 recruited patients (intention-to-treat), 57 received assay-directed chemotherapy and 53 were evaluable for all study end points (per protocol). The drug combinations used were gemcitabine + treosulfan, paclitaxel + cisplatin, paclitaxel + doxorubicin, and gemcitabine + cisplatin. The per protocol population could be divided into 22 (42%) chemosensitive and 31 (58%) chemoresistant patients by an arbitrary chemosensitivity index. Objective response was 36.4% in chemosensitive patients compared with 16.1% in chemoresistant patients (P = 0.114); progression arrest (complete response + partial response + stable disease) was 59.1% versus 22.6% (P = 0.01). Chemosensitive patients showed an increased overall survival of 14.6 months compared with 7.4 months in chemoresistant patients (P = 0.041). Conclusion:In vitro chemosensitivity testing may be worthy of further exploration to see if it could be a useful tool to predict the outcome of melanoma patients treated with a sensitivity-directed chemotherapy. Therefore, these preliminary results will be evaluated by a planned phase III trial using a randomized, standard-regimen controlled setting.
- 15 September 2006
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (18) , 5454-5463
In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group
Purpose:In vitro sensitivity assays are promising tools to predict the individual outcome of different chemotherapy regimens. However, a direct association between in vitro and in vivo chemosensitivity has to be shown by clinical studies. This multicenter phase II trial was aimed to investigate the efficacy of a sensitivity-directed, first-line chemotherapy in metastasized melanoma patients, and to prove an association between in vitro sensitivity and therapy outcome. Patients and Methods: The primary study end point was objective response; secondary end points were safety, overall survival, and progression-free survival. Viable tumor cells obtained from metastatic lesions were tested for chemosensitivity to seven single drugs and five drug combinations using an ATP-based luminescence viability assay. Results: Out of 82 recruited patients (intention-to-treat), 57 received assay-directed chemotherapy and 53 were evaluable for all study end points (per protocol). The drug combinations used were gemcitabine + treosulfan, paclitaxel + cisplatin, paclitaxel + doxorubicin, and gemcitabine + cisplatin. The per protocol population could be divided into 22 (42%) chemosensitive and 31 (58%) chemoresistant patients by an arbitrary chemosensitivity index. Objective response was 36.4% in chemosensitive patients compared with 16.1% in chemoresistant patients (P = 0.114); progression arrest (complete response + partial response + stable disease) was 59.1% versus 22.6% (P = 0.01). Chemosensitive patients showed an increased overall survival of 14.6 months compared with 7.4 months in chemoresistant patients (P = 0.041). Conclusion:In vitro chemosensitivity testing may be worthy of further exploration to see if it could be a useful tool to predict the outcome of melanoma patients treated with a sensitivity-directed chemotherapy. Therefore, these preliminary results will be evaluated by a planned phase III trial using a randomized, standard-regimen controlled setting.
- Open Access
- 14 June 2005
- Published by Wiley in International Journal of Cancer
- Vol. 117 (5) , 825-830
Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma
Proliferating cells express the pyruvate kinase isoenzyme type M2 (M2‐PK). This enzyme exists as an active tetramer and an inactive dimer. The dimeric form is predominantly found in tumor cells and is therefore termed Tumor M2‐PK (TuM2‐PK). TuM2‐PK molecules are released into the peripheral blood and may hereby function as a marker of tumor load in cancer patients. Our study was aimed to investigate TuM2‐PK as a potential plasma marker in melanoma patients compared to the well‐established serum marker S100β. We measured the concentration of TuM2‐PK in plasma and S100β in corresponding serum samples from 300 melanoma patients and 53 healthy controls using a sandwich ELISA and an immunoluminometric assay, respectively. Plasma concentrations of TuM2‐PK were significantly increased in melanoma patients compared to healthy controls (9.30 U/ml vs. 7.20 U/ml; p = 0.0036) and correlated with tumor load (p < 0.0005) and disease stage (p < 0.0005). Patients with elevated plasma TuM2‐PK (cut‐off = 15 U/ml) presented a reduced overall (p < 0.000005) and progression‐free (p = 0.023) survival. Multivariate analysis revealed plasma TuM2‐PK and serum S100β as independent predictors of overall survival in metastasized patients. Neither plasma TuM2‐PK nor serum S100β showed prognostic relevance for tumor‐free patients. Although the sensitivity and specificity to predict disease progression or death was higher for serum S100β compared to plasma TuM2‐PK, the combination of both markers improved the estimation of prognosis compared to that of serum S100β alone.
- 14 June 2005
- Published by Wiley in International Journal of Cancer
- Vol. 117 (5) , 825-830
Open AccessTumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma
Proliferating cells express the pyruvate kinase isoenzyme type M2 (M2‐PK). This enzyme exists as an active tetramer and an inactive dimer. The dimeric form is predominantly found in tumor cells and is therefore termed Tumor M2‐PK (TuM2‐PK). TuM2‐PK molecules are released into the peripheral blood and may hereby function as a marker of tumor load in cancer patients. Our study was aimed to investigate TuM2‐PK as a potential plasma marker in melanoma patients compared to the well‐established serum marker S100β. We measured the concentration of TuM2‐PK in plasma and S100β in corresponding serum samples from 300 melanoma patients and 53 healthy controls using a sandwich ELISA and an immunoluminometric assay, respectively. Plasma concentrations of TuM2‐PK were significantly increased in melanoma patients compared to healthy controls (9.30 U/ml vs. 7.20 U/ml; p = 0.0036) and correlated with tumor load (p < 0.0005) and disease stage (p < 0.0005). Patients with elevated plasma TuM2‐PK (cut‐off = 15 U/ml) presented a reduced overall (p < 0.000005) and progression‐free (p = 0.023) survival. Multivariate analysis revealed plasma TuM2‐PK and serum S100β as independent predictors of overall survival in metastasized patients. Neither plasma TuM2‐PK nor serum S100β showed prognostic relevance for tumor‐free patients. Although the sensitivity and specificity to predict disease progression or death was higher for serum S100β compared to plasma TuM2‐PK, the combination of both markers improved the estimation of prognosis compared to that of serum S100β alone.
- Open Access
- 20 April 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (8) , 1398-1405
Lack of clinical efficacy of imatinib in metastatic melanoma
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The primary study end point was objective response according to RECIST, secondary end points were safety, overall and progression-free survival. In all, 18 patients with treatment-refractory advanced melanoma received imatinib 800 mg day−1. In 16 evaluable patients no objective responses could be observed. The median overall survival was 3.9 months, the median time to progression was 1.9 months. Tumour biopsy specimens were obtained from 12 patients prior to imatinib therapy and analysed for c-kit, PDGF-Rα and -Rβ expression by immunohistochemistry. In four cases, cell lines established from these tumour specimens were tested for the antiproliferative effects of imatinib and for functional mutations of genes encoding the imatinib target molecules. The tumour specimens stained positive for CD117/c-kit in nine out of 12 cases (75%), for PDGF-Rα in seven out of 12 cases (58%) and for PDGF-Rβ in eight out of 12 cases (67%). The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect. In conclusion, this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-kit and PDGF-R.
- 20 April 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (8) , 1398-1405
Open AccessLack of clinical efficacy of imatinib in metastatic melanoma
This two-centre phase-II trial aimed at investigating the efficacy of imatinib in metastasised melanoma patients in correlation to the tumour expression profile of the imatinib targets c-kit and platelet-derived growth factor receptor (PDGF-R). The primary study end point was objective response according to RECIST, secondary end points were safety, overall and progression-free survival. In all, 18 patients with treatment-refractory advanced melanoma received imatinib 800 mg day−1. In 16 evaluable patients no objective responses could be observed. The median overall survival was 3.9 months, the median time to progression was 1.9 months. Tumour biopsy specimens were obtained from 12 patients prior to imatinib therapy and analysed for c-kit, PDGF-Rα and -Rβ expression by immunohistochemistry. In four cases, cell lines established from these tumour specimens were tested for the antiproliferative effects of imatinib and for functional mutations of genes encoding the imatinib target molecules. The tumour specimens stained positive for CD117/c-kit in nine out of 12 cases (75%), for PDGF-Rα in seven out of 12 cases (58%) and for PDGF-Rβ in eight out of 12 cases (67%). The melanoma cell lines showed a heterogenous expression of the imatinib target molecules without functional mutations in the corresponding amino-acid sequences. In vitro imatinib treatment of the cell lines showed no antiproliferative effect. In conclusion, this study did not reveal an efficacy of imatinib in advanced metastatic melanoma, regardless of the expression pattern of the imatinib target molecules c-kit and PDGF-R.
- 24 August 2004
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 30 (08/09) , P03
Manifestation einer systemischen Sklerodermie unter Therapie mit pegyliertem Interferon alpha bei metastasiertem Melanom
Eine 39jährige Patientin stellte sich im Juli 2002 mit links cervicalen, links supra- und infraclaviculären sowie mediastinalen Lymphknotenmetastasen eines malignen Melanoms bei unbekanntem Primarius in unserer dermato-onkolgischen Sprechstunde vor. Zwei Monate zuvor war bereits eine Axilladissektion links bei Metastasierung erfolgt. Von 08/02 bis 02/03 konnte unter einer Vakzinierungstherapie mit autologen Peptid beladenen dendritischen Zellen eine Remission der Erkrankung erzielt werden. Im Februar 2003 traten erneut Lymphknotenmetastasen cervical links, supraclaviculär beidseits, axillär rechts, mediastinal und subkutan periumbilikal auf. Daraufhin leiteten wir eine Chemoimmuntherapie mit Temozolomid und pegyliertem Interferon-alpha (PEG-IFN-alpha) ein. Beim ersten Staging im April 2003 wurde eine Remission aller Filiae verzeichnet, die insgesamt über 12 Monate stabilisiert werden konnte. Zwei Monate nach Beginn der Therapie klagte die Patientin erstmals über Kurzatmigkeit, und im CT der Lunge wurde der Verdacht auf ein pneumonisches Infiltrat geäußert. Eine internistische Abklärung ergab allerdings keinen Anhalt für eine Pneumonie. Sechs Monate nach Beginn der Interferon-Behandlung klagte die Patientin über weißlich-blaue Verfärbungen der Fingerendglieder, kalte Hände, Husten, Dyspnoe und Thoraxschmerzen bei Kälte, Gelenkbeschwerden und Mundtrockenheit. Parallel dazu wurde im CT der Verdacht auf eine Lungenfibrose des Lungenmantels geäußert. Die antinukleären Antikörper (ANA) im Serum waren mit 1:2560 bei granulärem Verteilungsmuster erhöht. Bis auf Jo1-Antikörper (Histidyl-tRNA-Synthetase) wurden keine weiteren spezifischen Antikörper nachgewiesen. Insbesondere die Scl-70 (DNA-Topoisomerase)-Antikörper waren negativ. Aufgrund der klinischen Symptomatik, des erhöhten ANA-Titers und der nachgewiesenen Lungenfibrose wurde die Diagnose einer systemischen Sklerodermie gestellt. Nach alleinigem Absetzen des PEG-IFN-alpha waren sowohl die pulmonale Symptomatik als auch die Veränderungen im CT der Lunge vollständig reversibel, so dass – auch im Hinblick auf die maligne Grunderkrankung – auf eine immunsuppressive Therapie verzichtet werden konnte. Lediglich der erhöhte ANA-Titer, der allerdings bereits vor Beginn der Interferon-Therapie bekannt war, blieb auch weiterhin bestehen. Dieser Fall demonstriert die Möglichkeit der Auslösung einer Autoimmunerkrankung unter Behandlung mit IFN-alpha bei bestehender Prädisposition sowie deren Reversibilität nach Absetzen des Interferons.
- 24 August 2004
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 30 (08/09) , P03
Manifestation einer systemischen Sklerodermie unter Therapie mit pegyliertem Interferon alpha bei metastasiertem Melanom
Eine 39jährige Patientin stellte sich im Juli 2002 mit links cervicalen, links supra- und infraclaviculären sowie mediastinalen Lymphknotenmetastasen eines malignen Melanoms bei unbekanntem Primarius in unserer dermato-onkolgischen Sprechstunde vor. Zwei Monate zuvor war bereits eine Axilladissektion links bei Metastasierung erfolgt. Von 08/02 bis 02/03 konnte unter einer Vakzinierungstherapie mit autologen Peptid beladenen dendritischen Zellen eine Remission der Erkrankung erzielt werden. Im Februar 2003 traten erneut Lymphknotenmetastasen cervical links, supraclaviculär beidseits, axillär rechts, mediastinal und subkutan periumbilikal auf. Daraufhin leiteten wir eine Chemoimmuntherapie mit Temozolomid und pegyliertem Interferon-alpha (PEG-IFN-alpha) ein. Beim ersten Staging im April 2003 wurde eine Remission aller Filiae verzeichnet, die insgesamt über 12 Monate stabilisiert werden konnte. Zwei Monate nach Beginn der Therapie klagte die Patientin erstmals über Kurzatmigkeit, und im CT der Lunge wurde der Verdacht auf ein pneumonisches Infiltrat geäußert. Eine internistische Abklärung ergab allerdings keinen Anhalt für eine Pneumonie. Sechs Monate nach Beginn der Interferon-Behandlung klagte die Patientin über weißlich-blaue Verfärbungen der Fingerendglieder, kalte Hände, Husten, Dyspnoe und Thoraxschmerzen bei Kälte, Gelenkbeschwerden und Mundtrockenheit. Parallel dazu wurde im CT der Verdacht auf eine Lungenfibrose des Lungenmantels geäußert. Die antinukleären Antikörper (ANA) im Serum waren mit 1:2560 bei granulärem Verteilungsmuster erhöht. Bis auf Jo1-Antikörper (Histidyl-tRNA-Synthetase) wurden keine weiteren spezifischen Antikörper nachgewiesen. Insbesondere die Scl-70 (DNA-Topoisomerase)-Antikörper waren negativ. Aufgrund der klinischen Symptomatik, des erhöhten ANA-Titers und der nachgewiesenen Lungenfibrose wurde die Diagnose einer systemischen Sklerodermie gestellt. Nach alleinigem Absetzen des PEG-IFN-alpha waren sowohl die pulmonale Symptomatik als auch die Veränderungen im CT der Lunge vollständig reversibel, so dass – auch im Hinblick auf die maligne Grunderkrankung – auf eine immunsuppressive Therapie verzichtet werden konnte. Lediglich der erhöhte ANA-Titer, der allerdings bereits vor Beginn der Interferon-Therapie bekannt war, blieb auch weiterhin bestehen. Dieser Fall demonstriert die Möglichkeit der Auslösung einer Autoimmunerkrankung unter Behandlung mit IFN-alpha bei bestehender Prädisposition sowie deren Reversibilität nach Absetzen des Interferons.
- 24 August 2004
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 30 (08/09) , V05
Das Serumproteomprofil als prognostischer Index beim malignen Melanom
Für das maligne Melanom existieren aktuell keine serologisch bestimmbaren Biomarker, die eine valide prognostische Einschätzung des einzelnen Patienten erlauben. Der weit verbreitete Serummarker S100-beta zeigt eine gute Korrelation mit der Tumorlast, ist jedoch für tumorfreie Patienten nur von geringer prädiktiver Relevanz. Neue hochauflösende massenspektrometrische Verfahren sind in Kombination mit bioinformatischer Technologie in der Lage, nicht nur einzelne Serumproteine, sondern das gesamte Serumproteom hinsichtlich seiner prädiktiven Relevanz zu analysieren. In der vorliegenden Studie wurden zunächst Serumproben von Melanompatienten in frühen Erkrankungsstadien (AJCC I; n=101) im Vergleich zu fortgeschrittenen Erkrankungsstadien (AJCC IV; n=104) mittels Chip-basierter MALDI-ToF Massenspektrometrie untersucht. Die erhaltenen Proteomprofile wurden über artifizielle neuronale Netzwerke auf spezifische Expressionsmuster überprüft. Hierbei wurden 94 der 205 Proben als „Trainings-Set“, 15 Proben als „Test-Set“ sowie 96 Proben als „Blind-Set“ eingesetzt. Nach erfolgter Trainings- und Testphase konnten mittels neuronaler Netzwerkalgorithmen 84 der 96 Proben (88%) des „Blind-Sets“ dem korrekten Erkrankungsstadium zugeordnet werden. In einer zweiten Versuchsserie wurden Serumproben, die von 55 Melanompatienten unmittelbar nach erfolgter Lymphknoten-Dissektion bei regionaler Metastasierung (AJCC III) entnommen worden waren, in gleicher Weise analysiert. Bei 28 dieser 55 Patienten kam es innerhalb des ersten postoperativen Jahres zu einem Erkrankungsprogress, während die restlichen 27 Patienten tumorfrei blieben. Über die bioinformatische Analyse der Serum-Proteom-Expressionsprofile konnten 44/55 Patienten (80%) korrekt ihrem Status als „Progressor“ oder „Nicht-Progressor“ zugeordnet werden. Hierbei wurden 23 (82%) der „Progressoren“ korrekt identifiziert, während über die Serum-S100-beta-Konzentration lediglich 6 (21%) dieser Patienten erkannt wurden. Diese ersten, präliminären Ergebnisse sind vielversprechend, müssen jedoch durch weitere Analysen an größeren Probenkollektiven validiert werden. Auf dieser Basis könnte die Proteom-Expressionsanalyse als wichtiges Hilfsmittel zur Einschätzung der Prognose von Melanompatienten dienen.
- 24 August 2004
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 30 (08/09) , V05
Das Serumproteomprofil als prognostischer Index beim malignen Melanom
Für das maligne Melanom existieren aktuell keine serologisch bestimmbaren Biomarker, die eine valide prognostische Einschätzung des einzelnen Patienten erlauben. Der weit verbreitete Serummarker S100-beta zeigt eine gute Korrelation mit der Tumorlast, ist jedoch für tumorfreie Patienten nur von geringer prädiktiver Relevanz. Neue hochauflösende massenspektrometrische Verfahren sind in Kombination mit bioinformatischer Technologie in der Lage, nicht nur einzelne Serumproteine, sondern das gesamte Serumproteom hinsichtlich seiner prädiktiven Relevanz zu analysieren. In der vorliegenden Studie wurden zunächst Serumproben von Melanompatienten in frühen Erkrankungsstadien (AJCC I; n=101) im Vergleich zu fortgeschrittenen Erkrankungsstadien (AJCC IV; n=104) mittels Chip-basierter MALDI-ToF Massenspektrometrie untersucht. Die erhaltenen Proteomprofile wurden über artifizielle neuronale Netzwerke auf spezifische Expressionsmuster überprüft. Hierbei wurden 94 der 205 Proben als „Trainings-Set“, 15 Proben als „Test-Set“ sowie 96 Proben als „Blind-Set“ eingesetzt. Nach erfolgter Trainings- und Testphase konnten mittels neuronaler Netzwerkalgorithmen 84 der 96 Proben (88%) des „Blind-Sets“ dem korrekten Erkrankungsstadium zugeordnet werden. In einer zweiten Versuchsserie wurden Serumproben, die von 55 Melanompatienten unmittelbar nach erfolgter Lymphknoten-Dissektion bei regionaler Metastasierung (AJCC III) entnommen worden waren, in gleicher Weise analysiert. Bei 28 dieser 55 Patienten kam es innerhalb des ersten postoperativen Jahres zu einem Erkrankungsprogress, während die restlichen 27 Patienten tumorfrei blieben. Über die bioinformatische Analyse der Serum-Proteom-Expressionsprofile konnten 44/55 Patienten (80%) korrekt ihrem Status als „Progressor“ oder „Nicht-Progressor“ zugeordnet werden. Hierbei wurden 23 (82%) der „Progressoren“ korrekt identifiziert, während über die Serum-S100-beta-Konzentration lediglich 6 (21%) dieser Patienten erkannt wurden. Diese ersten, präliminären Ergebnisse sind vielversprechend, müssen jedoch durch weitere Analysen an größeren Probenkollektiven validiert werden. Auf dieser Basis könnte die Proteom-Expressionsanalyse als wichtiges Hilfsmittel zur Einschätzung der Prognose von Melanompatienten dienen.
- 30 June 2004
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 53 (11) , 1051
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?
- 30 June 2004
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 53 (11) , 1051
Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?